Study guide
4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders
Certified Addictions Registered Nurse CARN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 CARN Exam Overview, Eligibility & Requirements 1.2 How to Use This Study Guide & Preparation Strategy
2 Chapter 2: Assessment & Screening
2.1 DSM-5-TR Substance Use Disorder Diagnostic Criteria & Severity Classification 2.2 Standardized Screening Tools: AUDIT, DAST-10, CAGE, CRAFFT & ASSIST 2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS 2.4 Neonatal & Special Population Assessment: Finnegan, Eat-Sleep-Console & Life Stages 2.5 Assessment of Co-Occurring Psychiatric & Medical Disorders
3 Chapter 3: Planning & Intervention
3.1 ASAM Criteria & Continuum of Placement Care 3.2 Motivational Interviewing (OARS) & Transtheoretical Stages of Change 3.3 Trauma-Informed Care Principles & Addictions Nursing Practice 3.4 Family Dynamics, Codependency, CRAFT Model & Family Support Systems 3.5 Nursing Diagnosis, Outcome Identification & Individualized Addictions Care Planning
4 Chapter 4: Clinical Management & Pharmacotherapy
4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention 4.2 Opioid Withdrawal Management & Symptom-Triggered Protocols 4.3 Medications for Opioid Use Disorder (MOUD: Methadone, Buprenorphine & Extended-Release Naltrexone) 4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders 4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services 4.6 Pain Management in Patients with Substance Use Disorders
5 Chapter 5: Substance-Specific Disorders, Prevention & Patient Education
5.1 Stimulant Use Disorders: Cocaine, Amphetamines & Caffeine 5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse 5.3 Cannabis & Hallucinogen Use Disorders 5.4 Tobacco Use Disorder, Vaping & Cessation Interventions 5.5 Prevention, Brief Intervention, Patient Education & Behavioral Addictions
6 Chapter 6: Evaluation, Recovery & Continuing Care
6.1 Relapse Prevention Models: Marlatt's Model, Urge Surfing & High-Risk Situations 6.2 Mutual-Help Groups & Peer Recovery Support: 12-Step, SMART Recovery & Peer Specialists 6.3 Recovery Capital, Social Determinants of Health & Holistic Wellness 6.4 Transitions of Care, Discharge Planning & Long-Term Recovery Management
7 Chapter 7: Professional Role, Ethics & Legal Issues
7.1 ANA/IntNSA Scope & Standards of Addictions Nursing Practice 7.2 Confidentiality Laws: 42 CFR Part 2 vs. HIPAA & 2024 Alignment Updates 7.3 Legal & Ethical Issues, Stigma Reduction & Person-First Language
4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders
Key Takeaways Explain This Topic AI
Naltrexone (50 mg oral daily or 380 mg IM monthly) blocks mu-opioid receptors, reducing alcohol reward and heavy drinking craving; contraindicated in acute hepatitis or liver failure (monitor LFTs).
Acamprosate (660 mg TID) modulates NMDA glutamate and GABA neurotransmission to maintain abstinence; excretes renally without hepatic metabolism, requiring dose adjustment in moderate renal impairment (CrCl 30–50 mL/min) and absolute contraindication in severe renal failure (CrCl <30 mL/min).
Disulfiram (250–500 mg daily) inhibits aldehyde dehydrogenase, causing toxic acetaldehyde accumulation if alcohol is consumed (disulfiram-alcohol reaction: severe flushing, vomiting, throbbing headache, hypotension); requires informed consent and normal baseline hepatic enzymes.
First-line Nicotine Use Disorder pharmacotherapy includes Nicotine Replacement Therapy (NRT: patch, gum, lozenge), Varenicline (partial alpha-4 beta-2 nicotinic agonist), and Bupropion SR (norepinephrine-dopamine reuptake inhibitor).
Combination NRT (long-acting nicotine patch combined with short-acting gum or lozenge) yields significantly higher long-term smoking cessation rates than single-agent NRT; varenicline represents the single most effective oral monotherapy.
Last updated: August 2026
- Pharmacotherapy for Alcohol & Nicotine Use Disorders
- Alcohol Use Disorder (AUD) Pharmacotherapy Overview
Pharmacotherapy plays a vital role in the comprehensive management of Alcohol Use Disorder (AUD), working synergistically with psychosocial interventions (e.g., Cognitive Behavioral Therapy, 12-step mutual aid groups). Three medications are currently FDA-approved for AUD: Naltrexone , Acamprosate , and Disulfiram . Selecting the appropriate agent requires evaluating patient recovery goals (abstinence vs. reduction in heavy drinking), hepatic function, renal clearance, and medication adherence potential.
- AUD Pharmacotherapeutic Agents
- 1. Naltrexone (Oral ReVia / Injectable Vivitrol)
Mechanism: Competitive antagonist at mu-opioid receptors. By blocking endogenous opioid release triggered by alcohol consumption, naltrexone reduces the euphoric "reward" of drinking and decreases alcohol craving.
Indication & Dosing: Oral: 50 mg PO daily. Injectable: 380 mg IM gluteal injection Q4 weeks.
Clinical Application: Effective for both total abstinence and reduction of heavy drinking (helps prevent a lapse from becoming a full relapse).
Safety & Monitoring: Contraindicated in patients taking prescribed opioids, those in acute opioid withdrawal, or patients with acute hepatitis/liver failure. Obtain baseline liver function tests (LFTs) ; monitor serum transaminases periodically.
2. Acamprosate (Campral)
Mechanism: Structural analogue of GABA that restores balance between neuronal excitation and inhibition by modulating NMDA glutamate receptors while enhancing GABA-A tone. It reduces the chronic "protracted withdrawal" distress (anxiety, insomnia, dysphoria) that triggers relapse.
Indication & Dosing: Standard dose: 660 mg PO three times daily (TID) (two 333 mg delayed-release tablets TID).
Clinical Application: Indicated for maintenance of abstinence in patients who have already achieved detoxification.
Renal Dosing Precautions: Acamprosate is cleared exclusively by the kidneys and does NOT undergo hepatic metabolism.
Moderate Renal Impairment (CrCl 30–50 mL/min): Reduce dose to 333 mg PO TID .
Severe Renal Impairment (CrCl < 30 mL/min): ABSOLUTELY CONTRAINDICATED .
Excellent choice for patients with severe liver disease or cirrhosis where naltrexone is unsafe.
3. Disulfiram (Antabuse)
Mechanism: Irreversible inhibitor of aldehyde dehydrogenase (ALDH) , the enzyme responsible for converting acetaldehyde to acetate during alcohol metabolism.
The Disulfiram-Alcohol Reaction: If alcohol is consumed while taking disulfiram, toxic levels of acetaldehyde accumulate rapidly in the bloodstream within 5–10 minutes, producing a severe, highly unpleasant physiological reaction: intense facial flushing, throbbing headache, nausea, severe vomiting, diaphoresis, tachycardia, chest pain, dyspnea, and hypotension.
Dosing & Administration: 250 mg to 500 mg PO daily. Patient must refrain from alcohol for at least 12 hours prior to the first dose.
Nursing Counseling: Disulfiram works via psychological deterrent . Patients must be educated to avoid hidden sources of alcohol (cough syrups, mouthwashes, hand sanitizers, cooking wines, aftershaves). The disulfiram-alcohol reaction can occur up to 14 days after discontinuing disulfiram due to slow enzyme regeneration.
AUD Pharmacotherapy Comparison Matrix
Agent Primary Target / Goal Primary Metabolism & Elimination Key Contraindications Nursing Safety Priorities
Naltrexone Reduces craving & heavy drinking reward Hepatic metabolism Acute hepatitis, liver failure, concurrent opioid use Baseline/periodic LFTs; verify opioid-free status
Acamprosate Maintains abstinence; reduces protracted withdrawal 100% Renal Elimination (No hepatic metabolism) Severe renal impairment (CrCl <30 mL/min) Assess renal function (CrCl); GI side effects (diarrhea)
Disulfiram Psychological deterrent (aversion therapy) Hepatic metabolism Severe coronary artery disease, psychosis, pregnancy Baseline LFTs; detailed education on hidden alcohol sources
Nicotine Use Disorder Pharmacotherapy
Tobacco use disorder remains the leading cause of preventable morbidity and mortality worldwide. First-line FDA-approved pharmacotherapies comprise Nicotine Replacement Therapy (NRT) , Varenicline , and Bupropion SR .
1. Nicotine Replacement Therapy (NRT)
NRT delivers controlled doses of therapeutic nicotine to relieve withdrawal symptoms without exposing the patient to toxic combustion products (tar, carbon monoxide).
Long-Acting Formulations: Nicotine Transdermal Patch (21 mg, 14 mg, 7 mg steps). Provides constant baseline nicotine levels over 16–24 hours.
Short-Acting Formulations: Nicotine Gum, Lozenge, Inhaler, Nasal Spray (2 mg and 4 mg strengths). Selected based on time-to-first-cigarette (TTFC): if patient smokes within 30 minutes of waking, start with 4 mg strength.
Combination NRT (Gold Standard): Combining a long-acting patch (baseline control) with a short-acting form (lozenge or gum for acute breakthrough cravings) achieves significantly higher quit rates than monotherapy.
2. Varenicline (Chantix)
Mechanism: Partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors . Provides moderate dopamine release to alleviate nicotine craving and withdrawal, while competitively blocking smoked nicotine from binding, reducing the rewarding effect of smoking.
Dosing Protocol: Titrated over 1 week (0.5 mg daily for 3 days, then 0.5 mg BID for 4 days, then 1 mg BID). Target quit date is set for Day 8 (or within 8–35 days of starting).
Side Effects & Nursing Care: Take with food and a full glass of water to minimize nausea. Educate regarding potential vivid dreams or insomnia.
3. Bupropion SR (Zyban / Wellbutrin)
Mechanism: Inhibits neuronal reuptake of norepinephrine and dopamine (NDRI) , mimicking nicotine's neurochemical actions on reward pathways.
Dosing Protocol: 150 mg PO daily for 3 days, then 150 mg PO BID (spaced at least 8 hours apart). Target quit date set after 1–2 weeks of treatment.
Black Box Warnings & Contraindications: Contraindicated in patients with seizure disorders , current or prior diagnosis of anorexia nervosa or bulimia , or undergoing abrupt withdrawal from alcohol/sedatives (lowers seizure threshold).